Seminars in Oncology
Volume 30, Issue 2 , Pages 121-126 , April 2003

Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

References 

  1. Kyle RA, Greipp PR, Gertz MA, et al.  Waldenstrom's macroglobulinemia: A prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol. 2000;108:737–742
  2. Buckle RM, Jenkins GC, Mills GL. Waldenstrom's macroglobulinemia treated with cyclophosphamide and chlorambucil. J Clin Pathol. 1996;19:55–59
  3. Kantarjian HM, Alexanian R, Koller CA, et al.  Fludarabine therapy in macroglobulinemic lymphoma. Blood. 1990;15:1928–1931
  4. Dimopoulos MA, O'Brien S, Kantarjian H, et al.  Fludarabine therapy in Waldenstrom's macroglobulinemia. Am J Med. 1993;95:49–52
  5. Zinzani PL, Gherlinzoni F, Bendandi M, et al.  Fludarabine treatment in resistant Waldenstrom's macroglobulinemia. Eur J Haematol. 1995;54:120–123
  6. Leblond V, Ben-Othman T, Deconinck E, et al.  Activity of fludarabine in previously treated Waldenstrom's macroglobulinemia: A report of 71 cases. Groupe Cooperatif Macroglobulinemie. J Clin Oncol. 1998;16:2060–2064
  7. Thalhammer-Scherrer R, Geissler K, Schwarzinger I, et al.  Fludarabine therapy in Waldenstrom's macroglobulinemia. Ann Hematol. 2000;79:556–559
  8. Foran JM, Rohatiner AZ, Coiffier B, et al.  Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol. 1999;17:546–553
  9. Dhodapkar MV, Jacobson JL, Gertz MA, et al.  Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: Results of United States intergroup trial (Southwest Oncology Group S9003). Blood. 2001;98:41–48
  10. Fenchel K, Wijermans P, Mitrou PS, et al.  Fludarabine is an effective agent in immunocytic lymphoma. Onkologie. 1994;17:508–513
  11. Dimopoulos MA, Kantarjian H, Estey E, et al.  Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med. 1993;118:195–198
  12. Delannoy A, Ferrant A, Martiat P, et al.  2-Chlorodeoxyadenosine therapy in Waldenstrom's macroglobulinaemia. Nouv Rev Fr Hematol. 1994;36:317–320
  13. Hellmann A, Lewandowski K, Zaucha JM, et al.  Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenstrom's macroglobulinemia. Eur J Haematol. 1999;63:35–41
  14. Dimopoulos MA, Weber DM, Kantarjian H, et al.  2-Chlorodeoxyadenosine therapy of patients with Waldenstrom macroglobulinemia previously treated with fludarabine. Ann Oncol. 1994;5:288–289
  15. White CA. Rituximab immunotherapy for non-Hodgkin's lymphoma. Cancer Biother Radiopharm. 1999;14:241–250
  16. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol. 2000;27(suppl 12):79–85
  17. Treon SP, Agus DB, Link B, et al.  CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother. 2001;24:272–279
  18. Byrd JC, White CA, Link B, et al.  Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidence of clinical activity. Ann Oncol. 1999;10:1525–1527
  19. Treon SP, Shima Y, Preffer FI, et al.  Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy. Semin Oncol. 1999;26(suppl 14):97–106
  20. Dimopoulos MA, Zervas C, Zomas A, et al.  Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol. 2002;20:2327–2333
  21. Sala R, Mauro FR, Bellucci R, et al.  Evaluation of marrow and blood haemopoietic progenitors in chronic lymphocytic leukaemia before and after chemotherapy. Eur J Haematol. 1998;61:14–20
  22. Dreger P, Kloss M, Petersen B, et al.  Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood. 1995;86:3970–3978
  23. Owen RG. Treatment options in Waldenstrom's macroglobulinaemia: The role of the purine analogues. Expert Opin Pharmacother. 2001;2:945–952
  24. O'Brien S, Kantarjian H, Estey E, et al.  Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med. 1994;330:319–322
  25. Delannoy A, Hanique G, Ferrant A. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med. 1993;328:812
  26. Juliusson G, Elmhorn-Rosenborg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med. 1992;327:1056–1061
  27. Laurencet FM, Zulian GB, Guetty-Alberto M, et al.  Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies. Br J Cancer. 1999;79:1215–1219
  28. Van Den Neste E, Louviaux I, Michaux JL, et al.  Phase I/II study of 2-chloro-2′-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Leukemia. 2000;14:1136–1142
  29. Kanelli S, Ansell SM, Habermann TM, et al.  Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. Leuk Lymphoma. 2001;42:1329–1337
  30. Case DC, Ervin TJ, Boyd MA, et al.  Waldenstrom's macroglobulinemia: Long-term results with the M-2 protocol. Cancer Invest. 1991;9:1–7
  31. Anagnostopoulos A, Dimopoulos MA, Aleman A, et al.  High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia. Bone Marrow Transplant. 2001;27:1027–1029
  32. Desikan R, Dhodapkar M, Siegel D, et al.  High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom's macroglobulinaemia. Br J Haematol. 1999;105:993–996
  33. Yang L, Wen B, Li H, et al.  Autologous peripheral blood stem cell transplantation for Waldenstrom's macroglobulinemia. Bone Marrow Transplant. 1999;24:929–930
  34. Myers B, Grimley C, Dolan G. Thalidomide and low-dose dexamethasone in myeloma treatment. Br J Haematol. 2001;114:245
  35. Dimopoulos MA, Zervas K, Kouvatseas G, et al.  Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol. 2001;12:991–995
  36. Coleman M, Leonard J, Lyons L, et al.  BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for treatment of myeloma and Waldenstrom's macroglobulinemia. Leuk Lymphoma. 2002;43:1777–1782
  37. Jane SM, Salem HH. Treatment of resistant Waldenstrom's macroglobulinemia with high dose glucocorticosteroids. Aust NZ J Med. 1988;18:77–78
  38. Dimopoulos MA, Zomas A, Viniou NA, et al.  Treatment of Waldenstrom's macroglobulinemia with thalidomide. J Clin Oncol. 2001;19:3596–3601
  39. Anagnostopoulos A, Giralt S. Stem cell transplantation (SCT) for Waldenstrom's macroglobulinemia (WM). Bone Marrow Transplant. 2002;29:943–947
  40. Ueda T, Hatanaka K, Kosugi S, et al.  Successful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenstrom's macroglobulinemia with severe pancytopenia. Bone Marrow Transplant. 2001;28:609–611
  41. Martino R, Shah A, Romero P, et al.  Allogeneic bone marrow transplantation for advanced Waldenstrom's macroglobulinemia. Bone Marrow Transplant. 1999;23:747–749
  42. Clark WF, Rock GA, Buskard N, et al.  Therapeutic plasma exchange: An update from the Canadian Apheresis Group. Ann Intern Med. 1999;131:453–462
  43. Buskard NA, Galton DA, Goldman JM, et al.  Plasma exchange in the long-term management of Waldenstrom's macroglobulinemia. Can Med Assoc J. 1977;117:135–137
  44. Avnstorp C, Nielsen H, Drachmann O, et al.  Plasmapheresis in hyperviscosity syndrome. Acta Med Scand. 1985;217:133–137
  45. Wicklund MP, Kissel JT. Paraproteinemic neuropathy. Curr Treat Options Neurol. 2001;3:147–156
  46. Gorson KC. Clinical features, evaluation, and treatment of patients with polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS). J Clin Apheresis. 1999;14:149–153
  47. Simovic D, Gorson KC, Ropper AH. Comparison of IgM-MGUS and IgG-MGUS polyneuropathy. Acta Neurol Scand. 1998;97:194–200
  48. Dyck PJ, Low PA, Windebank AJ, et al.  Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med. 1991;325:1482–1486
  49. Simmons Z. Paraproteinemia and neuropathy. Curr Opin Neurol. 1999;12:589–595
  50. Latov N. Neuropathy, heredity, and monoclonal gammopathy. Arch Neurol. 2000;57:641–642
  51. Latov N. Prognosis of neuropathy with monoclonal gammopathy. Muscle Nerve. 2000;23:150–152
  52. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology. 1999;52:1701–1704
  53. Dispenzieri A. Symptomatic cryoglobulinemia. Curr Treat Options Oncol. 2000;1:105–118
  54. Lamprecht P, Gause A, Gross WL. Cryoglobulinemic vasculitis resistant to intermittent intravenous pulse cyclophosphamide therapy. Scand J Rheumatol. 2000;29:201–202
  55. Mori Y, Kishimoto N, Imai Y, et al.  Cryofiltration and oral corticosteroids provide successful treatment for an elderly patient with cryoglobulinemic glomerulonephritis associated with hepatitis C virus infection. Intern Med. 2000;39:564–569
  56. Tavoni A, Mosca M, Ferri C, et al.  Guidelines for the management of essential mixed cryoglobulinemia. Clin Exp Rheumatol. 1995;13(suppl 13):S191–S195
  57. Takemori N, Hirai K, Onodera R, et al.  Durable remission after splenectomy for Waldenstrom's macroglobulinemia with massive splenomegaly in leukemic phase. Leuk Lymphoma. 1997;26:387–393
  58. Humphrey JS, Conley CL. Durable complete remission of macroglobulinemia after splenectomy: A report of two cases and review of the literature. Am J Hematol. 1995;48:262–266
  59. Nagai M, Ikeda K, Nakamura H, et al.  Splenectomy for a case with Waldenstrom macroglobulinemia with giant splenomegaly. Am J Hematol. 1991;37:140

☆ Address reprint requests to Waldenstrom's Macroglobulinemia Program, Dana Farber Cancer Institute, Harvard Medical School, LG100, 44 Binney St, Boston, MA 02115. Email: wmp@dfci.harvard.edu.

☆☆ 0093/7754/03/3002-0004$30.00/0

PII: S0093-7754(03)70061-X

doi: 10.1053/sonc.2003.50039

Seminars in Oncology
Volume 30, Issue 2 , Pages 121-126 , April 2003

Article Tools